TY  -  
T1  - Human papillomavirus vaccination : The ESGO-EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy 
SN  -  /  
UR  - http://hdl.handle.net/10138/311181 
T3  -  
A1  - Joura, Elmar A.; Kyrgiou, Maria; Bosch, Francisco X.; Kesic, Vesna; Nieminen, Pekka; Redman, Charles W. E.; Gultekin, Murat 
A2  -  
PB  -  
Y1  - 2019 
LA  - eng 
AB  - Vaccines against human papillomavirus (HPV) are available in Europe since 2006. They have been highly effective in preventing infection and disease caused by the vaccine types. Clinical efficacy data are available for cervical, vulvovaginal and anal precancer and invasive cervical cancer. Disease reduction is best with early vaccination and a coverage of more than 70%. Gender-neutral vaccination provides direct protection for all men and improves the coverage. A good coverage is followed by herd... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - HPV; Vaccination; Cervical cancer; Immunity; CIN; Cervical intraepithelial neoplasia; Prevention; CERVICAL INTRAEPITHELIAL NEOPLASIA; HPV VACCINE; COST-EFFECTIVENESS; WOMEN; INFECTION; ATTRIBUTION; EFFICACY; BIVALENT; PROGRAM; IMPACT; 3122 Cancers 
N1  -   
PP  -  
ER  -